Cannabis Business Tightens Regulations in New Jersey as Market Matures
New Jersey's cannabis market just entered a new phase of regulation. Governor Mikie Sherill signed Senate Bill 3945 into law last month, and it took effect this week, fundamentally reshaping how intoxicating hemp products move through the state's retail channels. 💰 MONEY MOVES Products containing more than 0.3 percent total THC—including delta-8, delta-10, THCA, and other naturally occurring intoxicating cannabinoids—are now exclusively available through licensed marijuana dispensaries, meaning they can no longer be purchased at gas stations, convenience stores, CBD shops, or smoke shops where they previously dominated shelf space. The change also prohibits online sales and vending machine distribution of these products to anyone under 21. The law creates a temporary window for hemp beverages under the Division of Alcoholic Beverage Control until November 13, when all intoxicating hemp products exceeding 0.4 milligrams of total THC must funnel exclusively into the state's licensed marijuana system.
The regulatory shift reflects a broader industry maturation: as cannabis normalization spreads across states, the distinction between "hemp" and "marijuana" is collapsing into administrative categories that track THC content rather than botanical identity. The New Jersey Cannabis Regulatory Commission has explicitly warned in-state hemp cultivators that if they plan to produce products exceeding the new April 13 limits, they must apply for marijuana cultivation or manufacturing licenses immediately—or face unlawful operation charges. This forces a clear choice: stay below the threshold and remain in the unregulated convenience-store economy, or go licensed and professional. 🚀 THIS IS COOL The move reflects genuine progress in how states approach cannabis science: regulators are now basing restrictions on actual cannabinoid profiles and dosing metrics rather than crude plant bans, treating the compound like a medicine or consumer product that can be measured, controlled, and distributed responsibly.
The timing aligns with pending federal hemp regulations expected to tighten on November 13—the same date New Jersey's permanent rules take effect. This synchronization suggests states are preparing for federal guidance that will likely harmonize interstate hemp commerce around THC thresholds and testing standards. For New Jersey's licensed marijuana retailers, this is significant: intoxicating hemp products that were previously scattered across thousands of retail touchpoints now consolidate into the state's controlled dispensary network. 💰 MONEY MOVES Licensed retailers gain exclusive access to an entire product category, potentially driving traffic and inventory turnover, while the state captures tax revenue and regulatory oversight of what was previously an unregulated gray market operating in plain sight at 7-Elevens and smoke shops.
What makes this moment worth examining: New Jersey is effectively admitting that hemp-derived intoxicating products are indistinguishable from marijuana in their effects and consumer appeal. The law doesn't ban them—it just routes them through the licensed system. This is pragmatism disguised as regulation. Rather than pretending the products don't exist or pose regulatory challenges, the state is saying: fine, they're legal, they're going to be sold, so let's control how and where. The parallel to alcohol regulation is instructive. Nobody tries to sell intoxicating beverages at gas stations and convenience stores without licensing, taxation, and age verification. Cannabis in New Jersey is now approaching that same framework, except the hemp beverage exemption creates a brief window where producers and retailers can pivot their operations.
🤔 THINK ABOUT IT Cannabis science now recognizes over 120 cannabinoids with distinct pharmacological effects, yet federal policy still treats the entire plant as Schedule I—meaning "no accepted medical use." Meanwhile, the FDA has already approved Epidiolex, a CBD-derived epilepsy medication. States are writing regulations around delta-8, delta-10, and THCA as consumer products. Medical patients use cannabis for chronic pain, glaucoma, and appetite support in licensed programs nationwide. So if the compounds are real enough to regulate, measure, and tax, and real enough for physicians to recommend, why hasn't federal classification caught up to state reality?
The New Jersey restrictions take effect as the broader cannabis business matures from gray-market chaos toward standardized retail infrastructure. Licensed operators now have clearer rules. State regulators have better control over supply chains. Consumers get tested products with labeled dosages. It's not legalization theater—it's the slow, administrative normalization of a plant that's been around for millennia and is now generating billions in documented economic activity across North America.
Ohio and Texas are moving in opposite directions on cannabis access this week, while federal lawmakers attempt to give states a lifeline on hemp products set to disappear come November.
An Ohio judge granted two smoke shop chains a temporary reprieve Thursday, allowing Happy Harvest and Get Wright Lounge to sell off existing inventory despite Senate Bill 56, which took effect March 20 and bans low-THC hemp products while capping THC in adult-use marijuana extracts at 70 percent and flower at 35 percent. Franklin County Judge Jeffrey M. Brown issued the temporary restraining order after hearing concerns about retailers holding thousands of dollars in now-illegal stock. 💰 MONEY MOVES Scott Pullins, attorney for the plaintiffs, explained the judge's reasoning plainly: "The judge here is concerned about retailers that have made big investments in inventory, and they can't move it, they can't transport it, they can't sell it." The businesses can only sell to adults 21 and older, and products must comply with packaging requirements. A preliminary injunction hearing is scheduled in two weeks, with Pullins suggesting they have "a good shot at least being able to continue in business through November"—when new federal hemp restrictions are set to take effect.
Meanwhile in Texas, voters are essentially ahead of their own government. A new poll by Trump's former chief pollster found that 75 percent of Texas registered voters support legalizing medical marijuana—including 85 percent of Democrats, 63 percent of Republicans, and 81 percent of independents. Yet only 11 percent of those voters have heard anything about the Texas Compassionate Use Program, which already provides limited access to low-THC medical cannabis for certain conditions. 🚀 THIS IS COOL When informed about recent legislative expansion that added chronic pain, traumatic brain injury, and Crohn's disease to the qualifying conditions list, support climbed to 62 percent across party lines. The disconnect suggests either a messaging failure or simply that expansion hasn't moved fast enough: 57 percent of voters agreed that "state leaders have moved too slowly in expanding and improving" the medical program.
Federally, a bipartisan Senate bill introduced Thursday offers an escape hatch for the coming hemp apocalypse. Senators Rand Paul (R-KY), Amy Klobuchar (D-MN), and Joni Ernst (R-IA) filed the Hemp Safety Enforcement Act, which would let states and Indian tribes opt out of a November 12 federal ban that redefines hemp so restrictively that only products containing 0.4 milligrams of total THC per container will remain legal. "This will wipe out the multi-billion-dollar industry, while depriving individuals of products they depend upon to improve sleep, relieve anxiety, and alleviate pain," Paul said. The bill requires states that opt out to implement a minimum age requirement for purchase and would permit interstate commerce between states that reject the federal ban. About half the states already have their own hemp regulatory frameworks, Paul noted, proving that "we can look out for public safety without trampling states' rights or adult choice."
🤔 THINK ABOUT IT The pattern emerging across these three stories is striking: judges are protecting businesses from overnight product bans, voters are saying they want more cannabis access than governments are providing, and Congress is quietly acknowledging that federal prohibition might be too blunt an instrument. Ohio's SB 56 didn't emerge from voter demand—the state's referendum effort failed to collect enough signatures. Texas voters weren't asked permission; they're being told what access they can have. Yet in all three cases, the pressure is moving toward normalization and practical regulation rather than away from it. The hemp ban was supposed to be inevitable. Now senators from both parties are offering states a way out.
Virginia's medical cannabis program is expanding, though unevenly across the state. Currently, licensed dispensaries operate in only two regions: RISE Christiansburg in Southwestern Virginia and two gLeaf locations—one in Richmond and one in Glen Allen—serving South Central Virginia. Northwestern and Northern Virginia have no dispensaries at this time, leaving large portions of the state without legal access to regulated cannabis for qualifying patients. The Virginia Cannabis Control Authority directs inquiries to medicalcannabis@cca.virginia.gov for program details and dispensary information.
The supply bottleneck comes as Virginia's governor signals movement on recreational legalization. Gov. Abigail Spanberger (D) recently defended significant amendments to a recreational marijuana legalization bill, explaining that she consulted with governors in other states with established cannabis markets before proposing her changes. "Every one of them said some version of make sure you get it right the first time and don't rush it because there will be things that come up," Spanberger said. Her cautious approach reflects real-world lessons from states further along in legalization—California, Colorado, Arizona, and others now generate billions in tax revenue but also face ongoing regulatory challenges around licensing, taxation, and black-market competition.
💰 MONEY MOVES The stakes are substantial. California remains the world's largest cannabis market, hitting $1.835 billion in mid-year sales in 2025 alone and generating over $275 million in taxes. As of early 2026, 24 states plus Washington D.C. have legalized recreational cannabis, while 40 states plus D.C. allow medical use. Colorado legalized recreational cannabis in 2012 and remains a leader in regulation and taxation. Arizona's recreational market, which launched in 2021, quickly became one of the fastest-growing in the U.S. For Virginia, getting the regulatory framework right before launch could mean capturing significant tax revenue and creating a legitimate economy around a plant that's been illegal for decades.
But federal uncertainty is creating chaos in the hemp industry right now. 💰 MONEY MOVES The hemp market—products with less than 0.3 percent delta-9 THC—has become a multi-billion-dollar industry since the 2018 Farm Bill legalized it. Now it faces extinction. Trump signed legislation late last year that will redefine hemp so that only products with 0.4 milligrams of total THC per container remain legal, effectively criminalizing the industry starting in November. Sen. Rand Paul (R-KY) and Sen. Amy Klobuchar (D-MN) are filing bipartisan legislation this week to let states opt out of the federal ban. "It's good for Kentucky farmers. It's a cash crop, kind of like tobacco," Paul said. Meanwhile, Missouri hemp businesses delivered 10,000 handwritten letters to Gov. Mike Kehoe asking him to veto a state bill that would ban intoxicating hemp products—potentially wiping out the entire industry in Missouri even if Congress reverses course federally.
The broader picture reveals a disconnect between what's legal and what's actually available to patients and consumers. Virginia offers medical cannabis access through just three dispensaries statewide while considering recreational legalization. Federally, the FDA has approved specific cannabinoid-based drugs—Epidiolex for seizures, Marinol and Syndros for chemotherapy nausea, Cesamet for similar purposes—yet the plant itself remains Schedule I, meaning researchers can't easily study it despite over 540 chemical compounds and mounting evidence for chronic pain relief and other therapeutic applications. 🚀 THIS IS COOL Epidiolex, a purified CBD drug derived from cannabis, was approved for treating Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy, demonstrating that cannabinoid science works when the regulatory environment allows it.
🤔 THINK ABOUT IT The federal government is about to criminalize a zero-overdose plant product (hemp THC) while keeping alcohol legal—a substance that kills approximately 95,000 Americans annually—and prescription opioids legal despite killing over 16,000 people per year. Meanwhile, Virginia is moving cautiously toward legalization after learning from other states' mistakes, but without a functioning medical dispensary network in two-thirds of the state. The plant is the same whether it's called cannabis, hemp, marijuana, or pot. The regulations treating them differently aren't based on the biology of the plant. They're based on policy decisions that shift with the political wind.
Cannabis businesses across Florida are expanding rapidly, with major dispensary chains establishing dominant footprints in key markets. GrowHealthy currently operates 25+ locations statewide, while competitors like MÜV and Curaleaf have established multiple Sarasota-area locations to capture the medical cannabis market. 💰 MONEY MOVES These dispensaries are offering regular promotions, rewards programs, and extended hours—typically 9 a.m. to 8:30 p.m.—to drive patient traffic and build customer loyalty in a competitive landscape where product selection (flower, concentrates, edibles, topicals, and vapes) has become table stakes for market entry.
But the cannabis industry faces serious regulatory crosswinds, particularly in states where politicians are moving to restrict products rather than embrace them. Missouri hemp businesses just mobilized 10,000 handwritten letters in just 10 days to Governor Mike Kehoe's office, urging him to veto legislation that would ban intoxicating hemp products statewide. The Missouri Hemp Trade Association argues the bill would "effectively eliminate an entire industry" regardless of what Congress ultimately decides about the federal hemp ban set for November 12.
Why Ban a Zero-Death Plant While Alcohol Kills 95,000 Americans Yearly?
Missouri's proposed hemp ban would restrict products like THC seltzers sold in bars and grocery stores, while the state continues to allow the sale of alcohol—a substance that causes far more documented deaths and disease than cannabis. The legislation creates a stricter environment than the federal government currently mandates, leaving hemp business owners and consumers with fewer options than they might have under federal law alone.
🎭 Rep. Dave Hinman (R-O'Fallon, Missouri) and Gov. Mike Kehoe (R-Missouri)
🗣️ Says:
“Support restricting intoxicating hemp products as part of public health and safety goals”
👁️ Does:
Maintain legal status for alcohol, which kills approximately 95,000 Americans annually—compared to cannabis overdose deaths: zero in recorded history
🎤 MIC DROPBanning a plant with zero overdose deaths while alcohol remains legal reveals a fundamental disconnect between stated safety goals and actual harm reduction.
The federal government's own tax code is adding friction to the cannabis workforce. 💰 MONEY MOVES The Internal Revenue Service just clarified that marijuana industry workers—budtenders, production staff, and other cannabis employees—cannot currently claim tips under President Trump's "No Tax on Tips" law. The IRS filing leaves open the possibility of eligibility "if cannabis is federally legalized," but for now, cannabis workers face a unique tax burden that workers in legal, regulated industries don't experience. Meanwhile, states like Pennsylvania are betting on cannabis revenue before legalization even happens: the Pennsylvania House passed Governor Josh Shapiro's budget plan that includes expected revenue from recreational marijuana sales—sales that technically don't yet exist in the state.
Beyond commerce, the human cost of cannabis criminalization remains staggering. Nearly 188,000 people were arrested for marijuana possession in 2024 alone, according to FBI data—representing 27 percent of all drug possession arrests in America. 🤔 THINK ABOUT IT Marijuana arrests now drive the overall war on drugs in multiple states: in five states (Idaho, Iowa, Louisiana, Nebraska, and Wisconsin), cannabis arrests exceeded 50 percent of total drug-related arrests last year. As the 4/20 holiday approaches, the Marijuana Policy Project is collecting arrest stories from people whose lives have been disrupted by criminalization, preparing a new report that combines raw enforcement data with personal narratives of trauma and disrupted lives.
Meanwhile, Maryland and other states are quietly normalizing cannabis use outside the recreational market. Maryland Governor Wes Moore signed legislation protecting veterinarians who recommend medical cannabis for animals from professional punishment—a small but telling shift toward treating cannabis as medicine rather than contraband. 🚀 THIS IS COOL The move reflects growing acceptance among medical professionals that cannabis has genuine therapeutic applications across species, signaling a broader shift in how states approach cannabis regulation. The cannabis industry's expansion in Florida, its regulatory challenges in Missouri, its tax complications at the federal level, and its slow acceptance in medical and veterinary contexts all point to the same reality: prohibition's framework is cracking, and the legal cannabis economy is building faster than regulators can manage.
Pennsylvania lawmakers advanced a bill Tuesday that would require hospitals and long-term care facilities to allow terminally ill patients to use medical cannabis on premises, with the House Health Committee approving HB 2254 in a 23-3 vote. Rep. Dan Frankel (D), who chairs the panel, sponsored the legislation, which would mandate that healthcare facilities develop written guidelines within 180 days of enactment. The bill permits medical marijuana use in hospitals, nursing facilities, assisted living residences, and personal care homes—provided it doesn't interfere with treatment plans and isn't vaporized in ways that could affect other patients' care. Facilities that violate the policy face civil penalties up to $500 per violation per day, though they're exempted from allowing use in emergency departments. The state Department of Human Services would be required to prepare sample marijuana plans for healthcare facilities and host at least five educational sessions on implementation.
The legislation arrives as Pennsylvania's governor pushes his own proposal to legalize recreational marijuana statewide. Rep. Frankel noted in his cosponsorship memo that Pennsylvania's existing Medical Marijuana Act was designed with terminally ill patients in mind, yet adoption of in-facility use remains inconsistent across the state. "Many terminally ill patients continue to face barriers to accessing medical cannabis during inpatient or end-of-life care," Frankel wrote, adding that the measure "will ensure patients have access to effective symptom relief while maintaining safety and compliance." A new poll of Pennsylvania likely voters shows that 69 percent support legalizing marijuana—with majority backing crossing party lines and spanning every age, racial, and geographic demographic.
🚀 THIS IS COOL New research from PAX, a vape device manufacturer, found that vaporizing cannabis reduces harmful inhaled byproducts by up to 99 percent compared to smoking joints. The study, conducted by PAX's director of product integrity Richard Rucker and senior chemist Derek Shiokari, analyzed 16 harmful or potentially harmful compounds (HPHCs) including benzene, formaldehyde, and acetaldehyde—substances released when cannabis is combusted. Vaporization heats cannabis below the combustion point while still releasing cannabinoids and terpenes. "Combustion produces harmful byproducts—whether it's tobacco, wood or cannabis," Rucker said in a statement. "By heating cannabis without burning it, vaporization significantly reduces the formation of these toxic compounds." The findings demonstrate that combustion itself—not the cannabis plant—is the primary driver of harmful inhalation exposure.
Meanwhile, Virginia Governor Abigail Spanberger (D) is seeking amendments to a recreational marijuana sales legalization bill, including a six-month delay to the market launch date. She also signed bills to protect marijuana consumers' parental rights and allow medical use in hospitals, while suggesting amendments to provide resentencing relief for prior cannabis convictions. 💰 MONEY MOVES Target is aggressively expanding its hemp-derived THC drinks business by obtaining 72 new lower-potency hemp edible licenses from the Minnesota Office of Cannabis Management, significantly scaling its entry into the legal hemp market. The retail giant's expansion signals growing mainstream commercial confidence in cannabis-adjacent products as federal-state legal gray areas continue to evolve.
On the federal level, Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Director Mehmet Oz filed a brief moving to dismiss a lawsuit from anti-marijuana groups seeking to block a plan to cover hemp products for eligible patients. The government's motion to dismiss was prepared in part by Matthew Zorn, an HHS lawyer who previously led cases suing government agencies on behalf of plaintiffs seeking marijuana and drug policy reform. 🤔 THINK ABOUT IT Between Pennsylvania's expanding medical access, new vaporization science reducing harm by 99 percent, major retailers entering the market, and the federal government itself defending hemp coverage—how much longer does the status quo of Schedule I classification actually reflect scientific evidence or public opinion?
Target is expanding its footprint in the hemp-derived THC beverage market, even as federal legislation looms to ban the products later this year. The Minnesota-based retailer has obtained licenses from state regulators to sell lower-potency hemp edibles—including THC drinks—at all 72 of its Target locations across Minnesota, up from a pilot program that involved just 10 stores last year. 💰 MONEY MOVES According to data from Minnesota's Office of Cannabis Management, Target now holds more lower-potency hemp edible licenses in the state than any other company. The new licenses, obtained on April 1, will remain valid for one year, allowing Target to sell beverages containing up to 10 milligrams of THC per container, well within Minnesota's regulatory framework that caps packages at 50 milligrams of THC total. The initial pilot launch included brands like Cann, Wynk, Indeed, and Surly—a diverse portfolio suggesting Target is treating this as a serious market segment rather than a novelty.
The timing reveals a calculated business decision. Congress passed and President Trump signed legislation that will recriminalize hemp-derived products containing more than 0.4 milligrams of THC per container, with enforcement set for November 2026. Despite bipartisan efforts in both chambers to delay the ban, leadership has not prioritized the delay. Yet Target is moving forward anyway, signaling confidence that either the legislation will face legal challenges, enforcement will be delayed, or the company sees enough runway in the next seven months to justify the expansion. 🚀 THIS IS COOL Consumer response has been measurable—a NuggMD poll found that 50.5 percent of respondents said they'd be more likely to shop at Target after learning about THC beverage sales, with over one-third specifically saying they'd visit stores that carry the products. This suggests Target identified a real demand signal and is capitalizing on it.
Meanwhile, federal health officials are fighting back against legal challenges to a different hemp initiative. Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare & Medicaid Services Director Mehmet Oz filed a brief asking a court to dismiss a lawsuit filed by anti-marijuana groups, including Smart Approaches to Marijuana, challenging a new Medicare coverage program that provides up to $500 annually in hemp-derived products—primarily CBD but including some THC—for eligible beneficiaries. The government's legal argument is straightforward: the plaintiffs lack standing. The brief notes that anti-cannabis advocacy organizations face no regulatory obligation from CMS and that the individual plaintiff, anti-marijuana lawyer David Evans, "opposes hemp products and will not use them." The filing argues that mere objection to a voluntary program does not constitute legal injury under Supreme Court precedent. This represents a notable shift in how the Trump administration is approaching cannabis policy compared to prior administrations.
State-level turbulence continues. A Texas judge issued a temporary restraining order preventing enforcement of new state rules that would restrict access to hemp-derived products like smokable THCA flower, pausing what would have been one of the most aggressive state-level crackdowns on the hemp market. The ruling came amid active litigation from industry groups challenging the restrictions. Simultaneously, Oregon Governor Tina Kotek signed legislation allowing patients to use medical cannabis in hospices and other healthcare facilities, and the Hawaii Senate passed resolutions calling on Congress to federally legalize marijuana while supporting state efforts to expunge cannabis conviction records and improve banking access for cannabis businesses. These competing state actions—Texas moving to restrict while Oregon and Hawaii move to expand—illustrate the fractured regulatory landscape cannabis businesses currently navigate.
🤔 THINK ABOUT IT The hemp industry now faces a peculiar moment. Target's aggressive expansion suggests market participants believe the federal ban won't be enforced uniformly or will face legal resistance, yet the November timeline creates genuine uncertainty. Federal officials are defending hemp coverage in Medicare, positioning it as a therapeutic option alongside more traditional pharmacological interventions. Meanwhile, some states are aggressively restricting hemp while others are expanding medical access and pushing federal legalization. For consumers—particularly Medicare beneficiaries and veterans who rely on THC products for chronic pain and PTSD—the coming months will determine whether these products remain accessible or become restricted again, and whether major retailers like Target continue carrying them or retreat from the category.
